UTHR vs. REGN, ALNY, BIIB, INCY, NBIX, EXEL, BMRN, EXAS, HALO, and RGEN
Should you be buying United Therapeutics stock or one of its competitors? The main competitors of United Therapeutics include Regeneron Pharmaceuticals (REGN), Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), Incyte (INCY), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Halozyme Therapeutics (HALO), and Repligen (RGEN). These companies are all part of the "biotechnology" industry.
United Therapeutics vs.
United Therapeutics (NASDAQ:UTHR) and Regeneron Pharmaceuticals (NASDAQ:REGN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, community ranking, earnings, profitability, risk, media sentiment and valuation.
United Therapeutics has a beta of 0.57, suggesting that its share price is 43% less volatile than the S&P 500. Comparatively, Regeneron Pharmaceuticals has a beta of 0.31, suggesting that its share price is 69% less volatile than the S&P 500.
Regeneron Pharmaceuticals has higher revenue and earnings than United Therapeutics. United Therapeutics is trading at a lower price-to-earnings ratio than Regeneron Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Regeneron Pharmaceuticals had 4 more articles in the media than United Therapeutics. MarketBeat recorded 30 mentions for Regeneron Pharmaceuticals and 26 mentions for United Therapeutics. United Therapeutics' average media sentiment score of 1.09 beat Regeneron Pharmaceuticals' score of 0.44 indicating that United Therapeutics is being referred to more favorably in the media.
United Therapeutics currently has a consensus price target of $393.00, indicating a potential upside of 39.68%. Regeneron Pharmaceuticals has a consensus price target of $836.48, indicating a potential upside of 59.78%. Given Regeneron Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Regeneron Pharmaceuticals is more favorable than United Therapeutics.
Regeneron Pharmaceuticals received 963 more outperform votes than United Therapeutics when rated by MarketBeat users. Likewise, 66.95% of users gave Regeneron Pharmaceuticals an outperform vote while only 62.62% of users gave United Therapeutics an outperform vote.
94.1% of United Therapeutics shares are owned by institutional investors. Comparatively, 83.3% of Regeneron Pharmaceuticals shares are owned by institutional investors. 10.3% of United Therapeutics shares are owned by company insiders. Comparatively, 7.0% of Regeneron Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
United Therapeutics has a net margin of 40.31% compared to Regeneron Pharmaceuticals' net margin of 31.07%. United Therapeutics' return on equity of 19.22% beat Regeneron Pharmaceuticals' return on equity.
Summary
Regeneron Pharmaceuticals beats United Therapeutics on 11 of the 19 factors compared between the two stocks.
Get United Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for UTHR and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
United Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:UTHR) was last updated on 6/10/2025 by MarketBeat.com Staff
